Source: Reuters Report, August 21, 2025

According to a Reuters report published on August 21, 2025, Johnson & Johnson (J&J) will invest $2 billion over the next decade to expand its biopharma manufacturing operations in Holly Springs, North Carolina. The announcement comes as the United States prepares to impose steep tariffs on imported pharmaceuticals.

The investment includes a 10-year partnership with Fujifilm Biotechnologies, which will provide J&J with a 160,000-square-foot facility. The project is expected to create approximately 120 new jobs in the region.

This latest move builds on J&J’s earlier pledge to increase U.S. investments by 25 percent, totaling more than $55 billion over four years. The broader plan also includes the construction of a new manufacturing plant in Wilson, North Carolina.

With tariffs on imported drugs potentially climbing as high as 250 percent, J&J joins other pharmaceutical giants such as Eli Lilly and AstraZeneca in ramping up domestic production to reduce risks tied to global trade.

Key Takeaways

Strengthening supply chains: Expanding U.S. production helps secure a reliable flow of medicines and reduces dependence on foreign imports.

Boosting the economy: The Holly Springs project is expected to add 120 new jobs and stimulate local growth.

Adapting to policy shifts: The move reflects a wider trend in the pharmaceutical industry to adjust strategies in response to changing trade rules.